Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation

Hematology
Wenli QiaoYan Xing

Abstract

Evaluation of therapeutic response in non-Hodgkin's lymphoma (NHL) patients with autologous stem cell transplantation (ASCT) is of great clinical significance. But the exact role of (18)F-fluorodeoxyglucose (FDG) imaging in NHL associated with ASCT is unclear. This study assessed the predictive value of (18)F-FDG hybrid PET/CT imaging for the clinical outcome such as progression-free survival (PFS) in patients with NHL prior to and after ASCT. (18)F-FDG hybrid PET/CT was performed in 31 patients (24 male and 7 female) with pathologically confirmed NHL prior to and after ASCT. Mean age was 43.1+/-13.8 years. No patients were lost to follow-up earlier than 1 year from ASCT. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of (18)F-FDG hybrid PET/CT before ASCT were compared to the results after ASCT. The results of pre- and post-ASCT FDG hybrid PET/CT findings were correlated to PFS using Kaplan-Meier survival analysis. Regression analyses were employed to test for independence of established prognostic factors. Sixteen of 31 patients (52%) progressed/relapsed or died after a median follow-up of 7 months, the remaining 15 patients (48%) were disease free after a median follow...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S FreedmanM J Robertson
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G P Canellos
Feb 7, 1998·Structure·B Strandberg
Oct 24, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Tatsuo TorizukaYasuomi Ouchi
Jun 28, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N G MikhaeelA R Timothy
Aug 16, 2005·Seminars in Nuclear Medicine·Guy JerusalemGeorges Fillet
Nov 5, 1993·Science

❮ Previous
Next ❯

Citations

Mar 26, 2013·Pediatric Radiology·Regine KlugeChristine Mauz-Körholz
Jun 28, 2011·Leukemia & Lymphoma·Heidi MocikovaTomas Kozak
Jul 31, 2012·Revista española de medicina nuclear e imagen molecular·A M Alvarez PáezA Serena Puig
Apr 3, 2016·Pediatric Blood & Cancer·Katell MichauxUNKNOWN SFCE and the EORTC children leukemia group
Nov 24, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Mateen C MoghbelLale Kostakoglu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.